Endocrine Abstracts

Current osteoporosis therapy is predominantly ‘anti-resorptive’. Oestrogen antagonises the action of RANK-Ligand, a potent cytokine for osteoclast differentiation. Amino-bisphosphonates inhibit the HMG CoA reductase pathway, reducing osteoclast activity and viability, while denosumab is a human monoclonal antibody that binds to RANKL. Denosumab treatment reduces fractures. In a study of 7868 women with postmenopausal osteoporosis, denosumab reduced new radiographic v...

Background: Decreased bone mineral density using dual energy absorptiometry (DXA) is reported in mixed cohorts of testosterone treated and testosterone naïve men with Klinefelter syndrome (KS). Bone mass and body composition in men with congenital anorchia (CA) have not been reported.Hypothesis: Men with KS and CA treated with testosterone from adolescence have normal bone mass and body composition.Methods: DXA and pQCT were p...